| abstract |
Cancers, particularly gastric cancer, hepatocellular carcinoma, ovarian cancer, colon cancer, and breast cancer, including human angiopoietin-2 (Ang2) alone and in combination with a VEGF pathway inhibitor are included. Providing antibodies useful for treating cancers caused by VEGFR2 and Ang2. The light chain includes light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences KASQDVYIAVA, YWASTRDT, and HQYSSYPPT, respectively, and the heavy chain is composed of GYSFTDYNMMV, YIDPYNGGTTGYNQKDFD, TRF, and TRF, respectively. An antibody that binds to Ang2, comprising the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3. [Selection figure] None |